Cobolimab

Phase 3Monoclonal antibody

GSK

Cobolimab is one of 72 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Cervical CancerActive, not recruiting

Lung Cancer (non-Small Cell)Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Lung Cancer (non-Small Cell)Preclinical

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cobolimab

GSK

Phase 3

5 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Pediatric

NCT06521567

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04446351

Q1 2027

PreclinicalActive, not recruiting

Lung Cancer (non-Small Cell)

NCT04655976

Q3 2027

Phase 2Active, not recruiting

Cervical Cancer

NCT06238635

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Active, not recruiting·MMeghan Shea·Phase 2·NCT06238635·66 enrolled

Advanced Solid Tumors1 trial

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04446351·107 enrolled

Selected Advanced Solid Tumors1 trial

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed· GSK logo

GSK·Phase 1·NCT02723955·829 enrolled

Pediatric1 trial

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Active, not recruiting· GSK logo

GSK·Phase 1/2·NCT06521567·83 enrolled

Lung Cancer (Non-Small Cell)1 trial

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

Active, not recruiting· GSK logo

GSK·Preclinical·NCT04655976·758 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cobolimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cobolimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cobolimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: GSK

Cobolimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Cervical Cancer1 trial

Advanced Solid Tumors1 trial

Selected Advanced Solid Tumors1 trial

Pediatric1 trial

Lung Cancer (Non-Small Cell)1 trial

References

Drug Info

Quick Facts

Related News